Obesity Treatment Research to Be Shared at November Event
New clinical trial data on weight loss medications and digital support tools will be presented at ObesityWeek 2026.
Updated on Oct. 31, 2026 in Weight Loss
Live Poll
Do you trust that new weight-loss drugs provide safe and effective long-term health benefits?
Novo Nordisk will present 26 clinical research abstracts at the ObesityWeek 2026 conference, taking place in Washington, D.C. from November 14 through November 17, 2026. These presentations will detail findings from studies on weight loss medications and patient support programs.
Why it matters
These upcoming reports offer insight into new clinical data, including trials testing weight management medications across diverse age groups and telehealth-based treatment delivery methods. The data may influence future conversations between patients and doctors regarding obesity care strategies.
The presentations encompass 26 clinical research abstracts, including the 3-month OCTANE study on oral semaglutide via telehealth and the 6-month SIGNAL study on Wegovy injection. Researchers will also share findings on the REDEFINE 9 trial, which tested CagriSema at 1.0 mg and 1.7 mg doses.
The players
Novo Nordisk
A pharmaceutical company that specializes in diabetes and obesity treatments including semaglutide-based injections and pills.
The details
The research focuses on several key areas of obesity management, including the use of digital patient support programs and telehealth platforms for medication adherence. Trials such as OPTIC compare treatment preferences across different age groups, while the STEP-YOUNG trial investigates semaglutide injection in children ages 6 to under 12. Investigators are also presenting data on bone mass metrics in relation to experimental agents.
Timeline
November 14-17, 2026: ObesityWeek 2026 conference takes place in Washington, D.C.
Saturday, November 14, 2026: REDEFINE 1 trial results are scheduled for presentation.
Sunday, November 15, 2026: The majority of poster and oral data sessions will occur.
Monday, November 16, 2026: Researchers will present data from the STEP-YOUNG trial.
Health Landscape
This story tracks the expansion of the STEP-YOUNG clinical trial program, which marks a notable effort to broaden weight management research into younger pediatric populations. It reflects a wider industry trend toward studying digital care delivery and specialized dosing for diverse age demographics.
Readers interested in these findings should consult their physician to discuss how emerging clinical data may affect future treatment options for obesity. It is important to note that therapies like CagriSema are not yet approved for use in the United States.
The takeaway
Ongoing clinical research continues to evaluate the effectiveness of new medications and digital delivery models for weight management. Patients should maintain communication with their healthcare providers regarding any changes in the standard of care or the availability of new treatment options.
Further reading
For more on the latest research in this area, visit our Weight Loss section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that new weight-loss drugs provide safe and effective long-term health benefits?
